Characteristics | Statistic (n = 248) |
---|---|
Design, n (%) | |
Randomized control trial | 108 (43.5) |
Non-randomized trial | 140 (56.5) |
Intervention type, n (%) | |
Pharmaceutical | 21 (8.5) |
Non-pharmaceutical | 227 (91.5) |
Number of study sites, n (%) | |
Single site | 143 (57.7) |
Multiple sites | 105 (42.3) |
Region, n (%) | |
Africa | 71 (28.6) |
Americas | 137 (55.2) |
Southeast Asia | 11 (4.4) |
Europe | 16 (6.5) |
Western Pacific | 8 (3.2) |
Mixed region | 5 (2) |
Country income level, n (%)a | |
High income | 151 (60.9) |
Upper-middle income | 37 (14.9) |
Lower-middle income | 25 (10.1) |
Low income | 33 (13.3) |
Mixed income | 2 (0.8) |
Qualitative methods, n (%) | 75 (30.2) |
Sample size: median (min, max) | 40 (3, 8794) |
Key population, n (%) | |
Contain any key population | 134 (54) |
Specific key populations, n (%) | |
Injection drug User | 4 (1.6) |
MSM | 20 (8.1) |
Incarcerated populations | 0 (0) |
Commercial sex workers | 1 (0.4) |
Pregnant women | 11 (4.4) |
Children | 5 (2) |
Youth | 28 (11.3) |
Indigenous | 0 (0) |
African, Caribbean, Black | 77 (31) |
Women | 24 (9.1) |
Transgender | 3 (1.2) |
Progression criteria prespecified, n (%) | 5 (2) |
Trial outcome, n (%) | |
Proceed to larger study | 65 (26.2) |
Do not proceed | 183 (73.8) |